fbpx

Invest in
stem cells
the building blocks
of the body

Invest in stem cells
the building blocks
of the body

Producing the next generation of IPSCs
Induced pluripotent stem cells therapies

Stem Cell Therapeutics

Pure Medical is developing next-generation IPSC stem cell immunotherapies combining its two proprietary platforms – Immunocell® biotherapeutics and Pluricision® targeted cell therapy. With this approach, the Company aims to address the lack of a durable response to current biological and immunotherapies as well as current high off-target toxicity experienced by most patients.

 

Pure Medical aims to enter the clinic with its lead Immunocell® programme in summer 2022. IPSCs are ethically derived from skin cells that have been reprogrammed back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes. For example, iPSCs can be stimulated into becoming beta islet cells to treat diabetes, blood cells to create new blood free of cancer cells for a leukaemia patient, or neurons to treat neurological disorders.

 

Using iPSC technology our scientists have reprogrammed skin cells into active motor neurons, egg and sperm precursors, liver cells, bone precursors, and blood cells. In addition, patients with untreatable diseases such as ALS, Rett Syndrome, Lesch-Nyhan Disease, and Duchenne’s Muscular Dystrophy donate skin cells to Pure Medical scientists for iPSC reprogramming research. The generous participation of patients and their families in this research enables Pure Medical scientists to study these diseases in the laboratory in the hope of developing new treatment technologies.

 

Pure Medical has established drug development partnerships with pharma and biotech, including a research collaboration with a number of leading universities. The Company is actively seeking commercialisation and collaboration deals with therapeutic companies to license its proprietary platforms in a range of therapeutic areas.

Imagine being able to repair blindness, heal MS, or rebuild your heart muscles following a heart attack. Research into stem cells, the building elements of tissues and organs, has raised the potential of medical breakthroughs like this for decades, but only a few treatments have been authorised.

But, according to Gary McCauley, CEO of Pure Medical Group, that could be about to change. “Stem cells are “within a few years of joining the medical mainstream,” much as gene therapy went from being a fantasy with little practical utility to becoming a major field of treatment.” Furthermore, advances in synthetic biology, the process of creating and re-engineering cells, may improve the effectiveness of stem cells.

How can stem cells help the body regenerate?

Stem cells are the body’s raw material, the basic cells that give rise to all other cells with specific roles. They can be present in the brain, blood, bone marrow, and skin, among other organs and tissues. According to Gary, the primary potential of stem cells is in regenerative medicine.

In order to make specialised cells, stem cells go through numerous rounds of division; “a blood stem cell can be utilised to produce blood cells, and skin stem cells can be used to produce skin cells.” So, in theory, pluripotent stem cells from one person may be transplanted into another to stimulate the creation of new cells and tissue.

However, because the amount of stem cells in a person’s body is limited and they are difficult to get, things have become more problematic in practice. Previously, scientists were also limited by the fact that stem cells could only produce one type of cell (blood stem cells, for example, could not produce skin cells).

Some scientists initially focused on stem cells from human embryos in their search for a universal stem cell, but this remains a contentious method, not only because harvesting stem cells necessitates the destruction of the embryo, but also because embryonic stem cells have a much higher risk of rejection by the recipient’s immune system.

 

The breakthrough

Why invest in Stem Cells? The good news is that technology for producing induced pluripotent stem cells was developed in 2006 by Japanese scientist Shinya Yamanaka of Kyoto University and his team (iPSC). The discovery, for which they were awarded the Nobel Prize in 2012, demonstrated that adult stem cells may be reprogrammed to become embryo-like stem cells. After that, these cells can be repurposed into any sort of stem cell. As a result, skin stem cells might be transformed into iPSCs, which could then be transformed into blood stem cells.

There are two significant advantages to this major breakthrough. For starters, because iPSCs are derived from adults, they do not have the ethical issues that embryonic stem cells do. Furthermore, because the cells come from another adult or are created by the patient, the chance of the body rejecting them is substantially reduced. According to Gary, scientists have developed this approach to the point where “we now have a blueprint for creating all types of cells” as well as an increased ability to multiply stem cells.

Invest In
Stem Cell Technology
MAKE AN ENQUIRY
Pure Medical is actively seeking partnerships and licensing opportunities. Contact us to make an enquiry.

 

Producing the next generation of IPSCs Induced pluripotent stem cells therapies

Stem Cell Therapeutics

Pure Medical is developing next-generation IPSC stem cell immunotherapies combining its two proprietary platforms – Immunocell® biotherapeutics and Pluricision® targeted cell therapy. With this approach, the Company aims to address the lack of a durable response to current biological and immunotherapies as well as current high off-target toxicity experienced by most patients.

 

Pure Medical aims to enter the clinic with its lead Immunocell® programme in summer 2022. IPSCs are ethically derived from skin cells that have been reprogrammed back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes. For example, iPSCs can be stimulated into becoming beta islet cells to treat diabetes, blood cells to create new blood free of cancer cells for a leukaemia patient, or neurons to treat neurological disorders.

 

Using iPSC technology our scientists have reprogrammed skin cells into active motor neurons, egg and sperm precursors, liver cells, bone precursors, and blood cells. In addition, patients with untreatable diseases such as ALS, Rett Syndrome, Lesch-Nyhan Disease, and Duchenne’s Muscular Dystrophy donate skin cells to Pure Medical scientists for iPSC reprogramming research. The generous participation of patients and their families in this research enables Pure Medical scientists to study these diseases in the laboratory in the hope of developing new treatment technologies.

 

Pure Medical has established drug development partnerships with pharma and biotech, including a research collaboration with a number of leading universities. The Company is actively seeking commercialisation and collaboration deals with therapeutic companies to license its proprietary platforms in a range of therapeutic areas.
Applications
Pure Medical proprietary Immunocell® biotherapeutics can be developed for a range of applications.

 

Pipeline
Pure Medical has a pre-clinical stage biopharmaceutical pipeline of Immunocell® therapeutic candidates.

 

READ MORE >
Partnerships
Pure Medical works with partners where there is a mutual interest in co-funding a development programme.

 

Become an
Investor in Health
MAKE AN ENQUIRY
Pure Medical is actively seeking partnerships and licensing opportunities. Contact us to make an enquiry.

 

Pure Medical Therapeutics Mobile Footer